Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.42 USD | +1.31% |
|
+0.43% | -13.64% |
06-14 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating | MT |
06-14 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.64% | 3.7B | |
+18.30% | 122B | |
+19.38% | 112B | |
-23.90% | 19.33B | |
-18.45% | 16.17B | |
-18.82% | 15.6B | |
-49.33% | 14.65B | |
+57.68% | 14.34B | |
+7.06% | 14B | |
+126.40% | 11.29B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Transcript : Ultragenyx Pharmaceutical Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 03